Novel perspectives on dendritic cell-based immunotherapy of cancer

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 6-10

  Bonaccorsi, Irene ^a,b   Pezzino, Gaetana ^a,b   Morandi, Barbara ^c   Ferlazzo, Guido ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer vaccines; Cell interactions; Dendritic cells; Immunotherapy; Lymph

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INTERACTION; CELL TRANSPORT; CYTOKINE PRODUCTION; CYTOLOGY; DRUG HALF LIFE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

CANCER VACCINES; CELL INTERACTIONS; DENDRITIC CELLS; IMMUNOTHERAPY; LYMPH;

ANIMALS; CANCER VACCINES; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 84887820850     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.021     Document Type: Review

References (41)

1. Cavallo F., Offringa R., van der Burg S.H., Forni G., Melief C.J. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006, 90:175-213.
2. Thumann P., Moc I., Humrich J., Berger T.G., Schultz E.S., Schuler G., et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003, 277:1-16.
3. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279-1288.
4. Bender A., Sapp M., Schuler G., Steinman R.M., Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996, 196:121-135.
5. Strobl H., Bello-Fernandez C., Riedl E., Pickl W.F., Majdic O., Lyman S.D., et al. flt3 ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 1997, 90:1425-1434.
6. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61:6451-6458.
7. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
8. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
9. Kalinski P., Vieira P.L., Schuitemaker J.H., de Jong E.C., Kapsenberg M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97:3466-3469.
10. Lee A.W., Truong T., Bickham K., Fonteneau J.F., Larsson M., Da Silva I., et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002, 20(Suppl 4):A8-A22.
11. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001, 98:8809-8814.
12. Montalto E., Mangraviti S., Costa G., Carrega P., Morandi B., Pezzino G., et al. Seroma fluid subsequent to axillary lymph node dissection for breast cancer derives from an accumulation of afferent lymph. Immunol Lett 2010, 131:67-72.
13. Morandi B., Bonaccorsi I., Mesiti M., Conte R., Carrega P., Costa G., et al. Characterization of human afferent lymph dendritic cells from seroma fluids. J. Immunol. 2013, (in press).
14. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
15. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-417.
16. Klein C., Bueler H., Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000, 191:1699-1708.
17. Larregina A.T., Morelli A.E., Tkacheva O., Erdos G., Donahue C., Watkins S.C., et al. Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood 2004, 103:811-819.
18. O'Neill D.W., Adams S., Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246.
19. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003, 63:2127-2133.
20. Holtl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002, 8:3369-3376.
21. O'Rourke M.G., Johnson M., Lanagan C., See J., Yang J., Bell J.R., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003, 52:387-395.
22. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999, 104:173-180.
23. Wang R.F., Wang H.Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 2002, 20:149-154.
24. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003, 198:1023-1034.
25. Fong L., Brockstedt D., Benike C., Wu L., Engleman E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001, 166:4254-4259.
26. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351.
27. Mocikat R., Braumuller H., Gumy A., Egeter O., Ziegler H., Reusch U., et al. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569.
28. Ferlazzo G., Munz C. Dendritic cell interactions with NK cells from different tissues. J Clin Immunol 2009, 29:265-273.
29. + T-cell-independent pathway for antitumor CTL induction. Blood 2005, 106:338-344.
30. Karimi K., Boudreau J.E., Fraser K., Liu H., Delanghe J., Gauldie J., et al. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther 2008, 16:411-418.
31. Shimizu K., Fujii S. DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol 2009, 39:457-468.
32. Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 2005, 101:12-17.
33. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002, 2:957-964.
34. Ferlazzo G. In vivo evidence for dendritic cell lysis by NK cells: hints on improving cancer vaccines by targeting NK cell activation. Oncoimmunology 2012, 1:1635-1636.
35. Morandi B., Mortara L., Chiossone L., Accolla R.S., Mingari M.C., Moretta L., et al. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One 2012, 7:e39170.
36. + T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol 2009, 21:599-606.
37. Munz C., Steinman R.M., Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005, 202:203-207.
38. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5:1260-1265.
39. Morandi B., Bougras G., Muller W.A., Ferlazzo G., Munz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006, 36:2394-2400.
40. Rizzello V., Bonaccorsi I., Dongarra M.L., Fink L.N., Ferlazzo G. Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics. J Biomed Biotechnol 2011, 2011:473097.
41. Dworacki G., Cicinnati V.R., Beckebaum S., Pizzoferrato E., Hoffmann T.K., De Leo A.B. Unpulsed dendritic cells induce broadly applicable anti-tumor immunity in mice. Cancer Biol Ther 2005, 4:50-56.